Literature DB >> 7436577

Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.

P Lewis, B L Hazleman, R Hanka, S Roberts.   

Abstract

Three hundred and eleven patients with classical or definite rheumatoid arthritis were observed over an 11-year period. This group is of particular interest since 214 patients were given cytotoxic therapy, 203 were treated with azathioprine (52 of these also received chlorambucil or cyclophosphamide), and 11 were treated with cyclophosphamide or chlorambucil alone. Forty-six patients died. This is an excess mortality compared with the expected rate for the general population matched with respect to age and sex. The death rate was higher than expected in the age group 45-64 years but lower in those aged 75 years or over. There were more deaths from neoplasia and ischaemic heart disease in the younger age group. One patient died of lymphosarcoma; treatment had been with corticosteroids, gold, and chloroquine. No other tumours of the reticuloendothelial system were recorded, and no patient developed leukaemia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436577      PMCID: PMC1000585          DOI: 10.1136/ard.39.5.457

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

1.  The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases.

Authors:  D A Gordon; J L Stein; I Broder
Journal:  Am J Med       Date:  1973-04       Impact factor: 4.965

2.  Malignancy and mortality in subacute rheumatoid arthritis in old age.

Authors:  G Moesmann
Journal:  Acta Rheumatol Scand       Date:  1969

3.  Letter: Additional risk from immunosuppressive therapy for rheumatoid arthritis.

Authors:  J D McCracken
Journal:  Ann Intern Med       Date:  1973-10       Impact factor: 25.391

4.  Immunosurveillance and cancer: epidemiological evidence.

Authors:  R Doll; L Kinlen
Journal:  Br Med J       Date:  1970-11-14

5.  Survivorship and death in rheumatoid arthritis.

Authors:  J Uddin; A S Kraus; H G Kelly
Journal:  Arthritis Rheum       Date:  1970 Mar-Apr

6.  Transitional cell carcinoma of the bladder associated with cyclophosphamide.

Authors:  G A Dale; R B Smith
Journal:  J Urol       Date:  1974-11       Impact factor: 7.450

7.  The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome.

Authors:  L G Anderson; N Talal
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

8.  Death rate and causes of death in patients with rheumatoid arthritis.

Authors:  H A Isomäki; O Mutru; K Koota
Journal:  Scand J Rheumatol       Date:  1975       Impact factor: 3.641

9.  Azathioprine in rheumatoid arthritis.

Authors:  M Mason; H L Currey; C G Barnes; J F Dunne; B L Hazleman; I D Strickland
Journal:  Br Med J       Date:  1969-02-15

10.  Skin cancer and immunosuppression.

Authors:  B K Walder; M R Robertson; D Jeremy
Journal:  Lancet       Date:  1971-12-11       Impact factor: 79.321

View more
  18 in total

Review 1.  Pathogenesis of rheumatoid arthritis: its relevance to therapy in the '90s.

Authors:  E D Harris
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

2.  Association between azathioprine therapy and lymphoma in rheumatoid disease.

Authors:  P I Pitt; A H Sultan; M Malone; V Andrews; E B Hamilton
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

Review 3.  What happens to patients with rheumatoid arthritis? The long-term outcome of treatment.

Authors:  T D Spector; D L Scott
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

Review 4.  [Primary CNS lymphoma in azathioprine therapy for autoimmune diseases: review of the literature and case report].

Authors:  F Kästner; W Paulus; M Deckert; P Schlegel; S Evers; I W Husstedt
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

5.  Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases.

Authors:  D P Symmons; M Ahern; P A Bacon; C F Hawkins; P L Amlot; E L Jones; P Prior; D L Scott
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

Review 6.  Immunosuppressive therapy in the treatment of autoimmune diseases.

Authors:  P A Miescher; P Beris
Journal:  Springer Semin Immunopathol       Date:  1984

7.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

8.  Long-term azathioprine in rheumatoid arthritis: a double-blind study.

Authors:  M De Silva; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

Review 9.  Depressed immunity and the development of cancer.

Authors:  I Penn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

10.  Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study.

Authors:  C C Erhardt; P A Mumford; P J Venables; R N Maini
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.